Add BrightSurf on Google Email

Immunotherapy drug is well tolerated in lung cancer patients with limited physical function, study suggests

A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.

SourceUniversity of Pittsburgh·JournalEClinicalMedicine·TypeRandomized controlled/clinical trial·DateNov 21, 2023

7 countries, 1.3 million lives lost – the devastating impact of tobacco revealed

A new study funded by Cancer Research UK reveals that smoking tobacco causes 20.8 million years of life loss each year, with four preventable risk factors contributing to over 30 million years of life lost annually. The study suggests that action on a global scale could save millions of lives from preventable cancers.

SourceCancer Research UK·JournalEClinicalMedicine·TypeData/statistical analysis·DateNov 15, 2023

Genetics of nearby healthy tissue may help catch lung cancer’s return

A new study suggests that analyzing genetic material from nearby healthy tissue may help predict lung cancer's return after treatment. The study analyzed RNA from tumor cells and adjacent, seemingly normal lung tissue and found that the expression of genes associated with inflammation was especially useful for making predictions.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalNature Communications·TypeExperimental study·DateNov 8, 2023

Lung cancer screening guidelines perpetuate racial disparities, Stanford-led study finds

A recent study led by Stanford Medicine researchers found that national lung cancer screening guidelines are less effective for African Americans than whites. An alternative risk-based method showed better results in eliminating disparities among races. The disparities persist despite guideline revisions implemented in 2021.

SourceStanford Medicine·JournalJAMA Oncology·TypeData/statistical analysis·DateOct 27, 2023

Antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer, delaying disease progression

A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.

Moffitt research finds non-small cell lung cancer drug lorlatinib targets additional protein

Researchers at H. Lee Moffitt Cancer Center & Research Institute demonstrate lorlatinib's activity against protein PYK2 in non-small cell lung cancer cells, revealing a potential path for repurposing the drug for other cancers. The study shows that combination therapy targeting ROS1, PYK2, and SRC results in enhanced cancer cell death ...

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalCell Chemical Biology·TypeExperimental study·DateOct 16, 2023

Improving follow-up of abnormal cancer screening results

A multilevel primary care intervention, including electronic health record reminders and patient outreach, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. The intervention was found to be effective in reducing missed screenings.

SourceJAMA Network·JournalJAMA·DateOct 10, 2023

Capturing immunotherapy response in a blood drop

A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.

SourceJohns Hopkins Medicine·JournalNature Medicine·DateOct 9, 2023

Should a more individualized model replace the current method for determining which people should be screened for lung cancer?

A new study found that an alternative model to identify patients with lung cancer eligible for screening was more accurate than the currently used method based on the United States Preventive Services Task Force (USPSTF) criteria. The PLCOm2012 models had higher sensitivity and identified more people with lung cancer eligible for scree...

SourceWiley·JournalCancer·DateOct 9, 2023

New study points to new possibilities for treating lung cancer patients

Researchers discovered that the short-chain fatty acid propionate can reduce metastases in mice with experimental lung cancer. The substance also increases the effectiveness of Cisplatin, a commonly used drug for lung cancer patients. Funding is now sought to identify patients who may benefit from propionate treatment.

SourceUniversity of Southern Denmark·JournalEMBO Molecular Medicine·TypeExperimental study·DateOct 9, 2023

Computer model predicts who needs lung cancer screening

A machine learning model developed by researchers can predict lung cancer risk with an 83.9% sensitivity, identifying those who need screening for the disease. The model uses just three predictors: age, smoking duration, and pack-years of smoking, making it a simplified approach to determine high-risk populations.

SourcePLOS·JournalPLOS Medicine·TypeComputational simulation/modeling·DateOct 3, 2023

Sylvester Research: Socioeconomic status linked with outcomes and survival in patients treated for non-small cell lung cancer

Researchers developed a scoring system analyzing income, education, geographical location, access to care, and other factors to identify patients at increased risk of poor outcomes. The study found significant socioeconomic disadvantage associated with a 21% decrease in textbook outcomes and a 32% decrease in overall survival.

SourceUniversity of Miami Miller School of Medicine·JournalJournal of Thoracic and Cardiovascular Surgery·DateSep 22, 2023

Kaiser Permanente cancer survival rates higher

Researchers found higher 5-year survival rates among Kaiser Permanente patients compared to National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) estimates. Improved screening rates, cancer treatment pathways, and coordinated care may have contributed to these higher survival rates.

SourceKaiser Permanente·JournalThe Permanente Journal·DateSep 20, 2023

Sylvester study shows how thoracic surgeons who treat lung cancer are helping to reduce patients’ risk of opioid dependence

A study by researchers at the University of Miami Miller School of Medicine found that thoracic surgeons who treat lung cancer are helping to reduce patients' risk of opioid dependence. The ERATS protocol, which includes intercostal nerve blocks and safe pain relievers, enables earlier hospital discharge with nearly opioid-free recovery.

Sylvester study shows that new protocols enable many patients to safely return home just one day after lung cancer surgery

A study at the University of Miami Miller School of Medicine found that robot-assisted surgeries and improved pain-management initiatives led to earlier discharges for many patients. However, lower-income patients were less likely to be discharged on day one due to socioeconomic disparities.

CityU and Asian Fund for Cancer Research sign MoU to jointly promote biomedical innovation and entrepreneurship; Harvard Medical School experts speak at the inaugural ‘Innovation Series in Biomedicine’ forum

CityU and AFCR have signed a MoU to promote cutting-edge cancer-related innovative inventions and commercialization. The partnership aims to foster the development of biomedicine and related innovation, with world-leading scholars from Harvard Medical School attending the inaugural 'Innovation Series in Biomedicine' forum.

Antioxidants stimulate blood flow in tumors

Researchers found that antioxidants activate a mechanism forming new blood vessels in tumor cells, which can help them grow and spread. The study suggests that dietary supplements containing antioxidants may accelerate tumour growth and metastasis in cancer patients.

SourceKarolinska Institutet·JournalJournal of Clinical Investigation·TypeExperimental study·DateAug 31, 2023

Statistician earns $1.7M to study long-term effects of neighborhood exposures and racial segregation on cancer risk

A statistician at Virginia Commonwealth University has been awarded a $1.7 million grant to investigate the long-term effects of neighborhood exposures and racial segregation on cancer risk. The researcher aims to better understand how geographic and socioeconomic factors contribute to disparities in cancer incidence and mortality.

Bioengineered tool unmasks cancer cells

A biomolecule has been engineered to selectively target and remove mucins from cancer cells, reducing tumor growth and increasing survival in lab-grown human cancer cells and mouse studies. This discovery could play a significant role in future therapies for cancer, as mucins are associated with many diseases.

SourceStanford University·JournalNature Biotechnology·DateAug 10, 2023

Swap-to-stop’ but let us shop - say vapers

A new study from the University of East Anglia found that most vapers believe a 'Swap-to-Stop' scheme providing free e-cigarettes would have helped them quit smoking. However, some respondents prefer to purchase e-cigarettes commercially due to personal preference for specific products.

SourceUniversity of East Anglia·JournalPerspectives in Public Health·TypeSurvey·DateAug 8, 2023